Arbutus Biopharma (ABUS) Competitors $4.11 -0.16 (-3.75%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$4.14 +0.03 (+0.73%) As of 10/10/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS vs. VKTX, AMRX, CNTA, XENE, CGON, QURE, RARE, APLS, IMVT, and GMTXShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Arbutus Biopharma vs. Its Competitors Viking Therapeutics Amneal Pharmaceuticals Centessa Pharmaceuticals Xenon Pharmaceuticals CG Oncology uniQure Ultragenyx Pharmaceutical Apellis Pharmaceuticals Immunovant Gemini Therapeutics Arbutus Biopharma (NASDAQ:ABUS) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Is ABUS or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -352.24%. Viking Therapeutics' return on equity of -19.98% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-352.24% -59.28% -44.11% Viking Therapeutics N/A -19.98%-19.38% Do analysts rate ABUS or VKTX? Arbutus Biopharma presently has a consensus target price of $5.00, suggesting a potential upside of 21.65%. Viking Therapeutics has a consensus target price of $86.42, suggesting a potential upside of 157.50%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Viking Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Does the media favor ABUS or VKTX? In the previous week, Viking Therapeutics had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 12 mentions for Viking Therapeutics and 6 mentions for Arbutus Biopharma. Viking Therapeutics' average media sentiment score of 0.68 beat Arbutus Biopharma's score of 0.31 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ABUS or VKTX? 43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, ABUS or VKTX? Arbutus Biopharma has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Which has higher earnings & valuation, ABUS or VKTX? Arbutus Biopharma has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.17M127.70-$69.92M-$0.29-14.17Viking TherapeuticsN/AN/A-$109.96M-$1.53-21.93 SummaryViking Therapeutics beats Arbutus Biopharma on 10 of the 16 factors compared between the two stocks. Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$818.55M$3.38B$6.12B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-14.1722.2585.8126.58Price / Sales127.70461.00612.51132.58Price / CashN/A47.2238.5062.09Price / Book8.0610.2112.756.53Net Income-$69.92M-$52.40M$3.31B$276.43M7 Day Performance-6.16%0.86%0.80%-0.88%1 Month Performance-16.12%10.39%6.21%3.55%1 Year Performance5.93%27.24%80.34%37.91% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma1.7266 of 5 stars$4.11-3.7%$5.00+21.7%+8.4%$818.55M$6.17M-14.1790News CoveragePositive NewsAnalyst ForecastVKTXViking Therapeutics3.9284 of 5 stars$32.28+8.6%$86.42+167.7%-46.3%$3.34BN/A-21.1020Analyst ForecastGap UpAMRXAmneal Pharmaceuticals3.0518 of 5 stars$10.55+1.5%$12.00+13.7%+17.8%$3.26B$2.85B1,056.068,100Analyst ForecastCNTACentessa Pharmaceuticals2.8916 of 5 stars$23.00-1.0%$32.38+40.8%+42.5%$3.11B$6.85M0.00200Analyst ForecastXENEXenon Pharmaceuticals2.618 of 5 stars$39.55-0.2%$53.30+34.8%-1.9%$3.05B$9.43M-11.14210Analyst ForecastAnalyst RevisionCGONCG Oncology2.1109 of 5 stars$38.13-4.2%$56.55+48.3%+25.4%$3.04B$1.14M0.0061Trending NewsAnalyst ForecastInsider TradeQUREuniQure3.2715 of 5 stars$52.91-3.7%$71.75+35.6%+1,035.8%$3.01B$27.12M-13.50500News CoverageAnalyst ForecastAnalyst RevisionRAREUltragenyx Pharmaceutical4.3196 of 5 stars$30.19-3.3%$81.50+170.0%-41.6%$3.01B$560.23M-5.461,294News CoverageAnalyst ForecastAPLSApellis Pharmaceuticals4.0377 of 5 stars$24.36+2.4%$33.29+36.7%-5.7%$3.01B$781.37M0.00770Analyst ForecastIMVTImmunovant1.8146 of 5 stars$16.55-2.1%$33.20+100.6%-43.1%$2.95BN/A0.00120News CoverageGMTXGemini TherapeuticsN/A$67.78+2.9%N/A+51.3%$2.94BN/A-67.7830News Coverage Related Companies and Tools Related Companies VKTX Alternatives AMRX Alternatives CNTA Alternatives XENE Alternatives CGON Alternatives QURE Alternatives RARE Alternatives APLS Alternatives IMVT Alternatives GMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABUS) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
